An update on the discovery and development of selective heat shock protein inhibitors as anti-cancer therapy. (3rd October 2018)

• Record Type: Journal Article
• Authors: Olotu, Fisayo; Adeniji, Emmanuel; Agoni, Clement; Bjij, Imane; Khan, Shama; Elrashedy, Ahmed; Soliman, Mahmoud
• Is Part Of: Expert opinion on drug discovery. Volume 13:Number 10(2018:Oct.)
• Page Start: 903
• Page End: 918
• Publication Date: 2018-10-03
• Subjects: Heat shock proteins -- computer-aided drug design -- oncogenic -- selectivity -- toxicity; 615.1
• DOI: 10.1080/17460441.2018.1516035
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : Over the years, not a single HSP inhibitor has progressed into the post-market phase of drug development despite the success recorded in various pre-clinical and clinical studies. The inability of existing drugs to specifically target oncogenic HSPs has majorly accounted for these setbacks. Recent combinatorial strategies that incorporated computer-aided drug design (CADD) techniques are geared towards the development of highly specific HSP inhibitors with increased activities and minimal toxicities. Areas covered : In this review, strategic therapeutic approaches that have recently aided the development of selective HSP inhibitors were highlighted. Also, the significant contributions of CADD techniques over the years were discussed in detail. This article further describes promising computational paradigms and their applications towards the discovery of highly specific inhibitors of oncogenic HSPs. Expert opinion : The recent shift towards highly selective and specific HSP inhibition has shown great promise as evidenced by the development of paralog/isoform-selective HSP drugs. It could be further augmented with computer-aided drug design strategies, which incorporate reliable methods that would greatly enhance the design and optimization of novel inhibitors with improved activities and minimal toxicities.